Clinical trial
Late Onset Alzheimer's Disease
Name
AAAP0479
Description
The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to participate.
Trial arms
Trial start
2016-11-15
Estimated PCD
2026-09-01
Trial end
2026-09-01
Status
Recruiting
Treatment
Blood Draw
Collection of blood samples for genetic testing
Arms:
Families with a history of Alzheimer's Disease, Individuals with Dementia (Alzheimer's Disease), Un-related, non-demented controls
Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test
Memory Test
Arms:
Families with a history of Alzheimer's Disease, Individuals with Dementia (Alzheimer's Disease), Un-related, non-demented controls
Size
10000
Primary endpoint
Total number of genes identified to be associated with the risk of AD
5 years
Eligibility criteria
Inclusion Criteria:
* Established diagnosis of definite or probable AD or have a diagnosis of a related neurodegenerative disorder such as Frontotemporal Dementia (FTD) or Lewy Body Dementia (LBD) (will also recruit sporadic FTD and LBD) cases.
* a living sibling with probable or possible AD;
* a third living relative affected with AD (onset age 50 or older) or unaffected (60 or older);
* participants in the proband's generation with an identified companion serving as an informant;
* participants who have capacity to consent or participants lacking capacity to consent with a surrogate/proxy in place to provide consent.
Exclusion Criteria:
* failure to identify an appropriate informant;
* uncertainty of the clinical diagnosis of Alzheimer's disease or other related disorder;
* discovery of additional diagnosis that could account for the clinical manifestations;
* unwillingness to participate;
* failure to identify a living sibling with AD or other related disorder (except in the cases of sporadic FTD and sporadic LBD);
* participants lacking the capacity to consent who do not have a surrogate or proxy or next of kin to provide consent.
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'FAMILY_BASED', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Blood and samples from autopsy/brain tissue.'}, 'enrollmentInfo': {'count': 10000, 'type': 'ESTIMATED'}}
Updated at
2024-05-16
1 organization
Organization
Columbia University